Could a single infusion of 'Peacekeeper' cells let kidney transplant patients ditch most of their meds?
NCT ID NCT06552169
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a single infusion of a patient's own regulatory T cells (TRK-001) can prevent the immune system from attacking a new kidney. 34 living-donor kidney transplant recipients will either receive standard anti-rejection drugs alone or those drugs plus the cell infusion. The goal is to see if the cell therapy allows patients to safely reduce to just one anti-rejection medication a year after transplant, while avoiding rejection and other complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
regulatory T cells (TRK-001) plus standard immunosuppression drugs
What this could lead to
If successful, this could allow kidney transplant recipients to safely reduce their lifelong anti-rejection medications to just one drug, lowering side effects and improving quality of life.
What could go wrong
This is a small, early-phase trial (34 people) testing safety and feasibility. The cell therapy may not work as hoped, and reducing immunosuppression could increase rejection risk. Long-term benefits are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang Gung Medical Foundation Hospital
RECRUITINGTaoyuan, 333, Taiwan
Contact
-
Mayo Clinic in Arizona
RECRUITINGPhoenix, Arizona, 85054, United States
Contact
-
Mayo Clinic in Minnesota
RECRUITINGRochester, Minnesota, 55905, United States
Contact
-
National Cheng Kung University Hospital
NOT_YET_RECRUITINGTainan, 704, Taiwan
Contact
-
National Taiwan University Hospital
RECRUITINGTaipei, 100229, Taiwan
Contact
-
Northwestern Memorial Hospital
RECRUITINGChicago, Illinois, 60611, United States
Contact
-
Taichung Veterans General Hospital
RECRUITINGTaichung, 407219, Taiwan
Contact